Kyverna reported $369.8M in cash, cash equivalents, and available-for-sale marketable securities as of March 31, inclusive of approximately $336.2M in net proceeds raised from its initial public offering that was completed in February, after deducting underwriting discounts and commissions and other offering costs. “We continue to build momentum in the clinical development of our lead product candidate, KYV-101, as we seek to bring autoimmune CAR T-cell therapies to more patients across both the US and Europe,” said Peter Maag, CEO of Kyverna. “We are excited to build on our leadership position in 2024 and continue to execute diligently on our promise to bring hope to patients living with autoimmune disorders.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYTX:
- Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
- Kyverna Therapeutics added to Analyst Focus List at JPMorgan
- Kyverna Therapeutics treatment of myasthenia gravis granted orphan status
- Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results